<?xml encoding="utf-8" ?> Editor’s note: This story and headline have been corrected to reflect that BNT122 is a BioNTech and ...

Merck & Co. (NASDAQ:MRK) extended its bullish run into a seventh straight session, with shares trading 1.56% higher at $121.62 on Friday afternoon. Over the preceding six sessions, the company’s ...

MRK remains a defensive, yield-generating diversification play, but near-term upside appears constrained by valuation and ...

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...

Merck (MRK) stock surged 12.12% after positive Phase 3 melanoma trial results with Moderna showed improved survival rates for ...

Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming ...

A Barchart report shows that despite recent strong Q2 results and a 10% spike in Merck stock today, an unusually large volume of put options has traded at a much lower strike price. Is MRK stock ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 13 trades. If we consider the specifics ...

Oncology R&D organization Sarah Cannon Research Institute (SCRI) announced a collaboration with Merck & Co. to bolster patient access to community-based oncology trials. | Oncology R&D organization ...